Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: A phase II study

Oncology

Volumn 72, Issue 5-6, 2008, Pages 279-284

  Endlicher, E ^a   Troppmann, M ^a   Kullmann, A ^a   Golder S ^a   Herold, T ^a   Herfarth, H ^a   Grossmann, J ^a   Schlottmann, K ^a   Kullmann, F ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

5 Fluorouracil; Chemotherapy; Gemcitabine; Irinotecan; Pancreatic cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; RAPAMYCIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; LEUKEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 39049169917     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113039     Document Type: Article

References (21)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Mallinson CN, Rake MO, Cocking JB, et al: Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980;281:1589-1591.
3. Palmer KR, Kerr M, Knowles G, et al: Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994;81:882-885.
4. Glimelius B, Hoffman K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996;7:593-600.
5. Shore S, Raraty MGT, Ghaneh P, et al: Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003;18:1049-1069.
6. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
7. Rocha Lima CM, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 2002;20:1182-1191.
8. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3786.
9. Shiah HS, Cheng AL, Hsu C, et al: Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol 2006;21:531-536.
10. Bahadori HR, Rocha Lima CM, Green MR, et al: Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res 1999;19:5423-5428.
11. Schlottmann K, Friedrich A, Messmann H, et al: A phase I study of irinotecan (I), gemcitabine (G), and 5-fluorouracil (5-FU) in patients with advanced gastrointestinal cancers. Eur J Cancer 2001;37(suppl 6):A1066.
12. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981;47:207-214.
13. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-1438.
14. Moore MJ, Hamm J, Dancey J, et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-3302.
15. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-167.
16. Richards DA, Boehm KA, Waterhouse DM, et al: Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006;17:1096-1102.
17. Heinemann V, Labianca R, Hinke A, Louvet C: Increased survival using platinum analog combined with gemcitabine as compared to single agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German multicenter study. Ann Oncol 2007;18:1652-1659.
18. Storniolo AM, Enas MH, Brown CA, et al: An investigational new drug treatment program for patients with gemcitabine. Cancer 1999;85:1261-1268.
19. Stathopoulos GP, Syrigos K, Aravantinos G, et al: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587-592.
20. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;24:4441-4447.
21. Cunningham D, Chau I, Stocken D, et al: Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005;3(suppl 4):PS11.